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Plain language summary: Copy number variants – increases or decreases in the inherited “dosages” or 
one or more important genes – are increasing recognized in clinical psychiatry. We call for a clinical 
crowd-sourcing, for more systematic case reports to help clinicians identify sound treatment options. 
Abstract: Specific copy number variants (CNVs) have been robustly associated with intellectual disability, 
autism, and schizophrenia. Most of the literature focus has been on documenting the existence of these 
phenomena. There are few data to guide therapeutic choices for these “orphan” diseases. We call for 
systematic and longitudinal case reports which, if carefully conducted, may provide crucial initial 
knowledge to guide therapeutics. We provide a step-by-step overview, a tailored set of consensus 
criteria for high-quality case reports, and a specific set of learning resources.  
 
Imagine an initial psychiatric interview that begins with the chief complaint, “I have a de novo 16p11 
duplication and they say I have schizophrenia and Asperger’s. What does this mean for me and my 
family? How can you help me?” Provided that the patient’s report can be verified, this chief complaint 
has a strong scientific empirical basis. As the patient says, this “copy number variant” or CNV results in 
changes in the number of copies of ~30 genes located on a 600,000 base pair region on the short arm of 
chromosome 16, and this rare genetic mutation increases risk for autism and schizophrenia 
(Supplemental Note 1). How exactly would you help? What evidence would support your clinical 
choices? On the basis of current knowledge, a clinician should explore the possibility of other psychiatric 
diagnoses (e.g., major depression and speech and language delay) and be alert for the presence of 
physical abnormalities including renal and urinary malformations as well as consider the need for 
genetic counseling. However, while there may be broader implications for the patient and their family, 
to the best of our knowledge, there are few relevant data that inform the psychiatric management of 
this patient. Thus, how can our field cooperate in order to rapidly increase knowledge relevant to clinical 
management?  
Although this scenario might seem far-fetched, genetic evaluations are increasingly part of standard-of-
care in psychiatry. A “genetic workup” is increasingly part of the clinical evaluation of children with 
moderate/severe intellectual disability, marked developmental delay, and autism, and is justifiable for 
adults who present similarly or who have complex presentation (see below). In fact, psychiatrists who 
treat individual with severe psychiatric disorders (including ourselves) are certain to have encountered 
patients with important genetic changes – and we probably did not know it. The rapid pace of progress 
in medical genomics means that these topics and their implications will be unfamiliar to many clinicians, 
and a number of educational resources are available (Table S1).  
Normally, children inherit a paternal and a maternal copy of every autosome (chromosomes 1-22). 
Occasionally, there are errors in the meiotic or mitotic machinery so that large regions, often containing 
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multiple genes, are lost or gained. Such changes are termed CNVs. These can occur at the level of a 
whole chromosome (e.g., trisomy 21, 48.1 megabases) or at finer levels (hundreds of kilobases or 
smaller as with the 16p11 CNV). Many pathogenic CNVs recur due to regional genomic features and can 
be found worldwide (1). Genomic studies have established the etiological importance of specific CNVs 
for psychiatric outcomes, with most of these CNVs associated with variable outcomes (pleiotopy) 
including moderate/severe intellectual disability, developmental delay, autism, tics, dyscoordination, 
and schizophrenia (Figure 1a).  
In samples seen in clinical psychiatry, current estimates suggest that a clinically- or etiologically-relevant 
CNV is likely to be present in around 2-3% of people with schizophrenia, 10% of people with autism, and 
25% or more of people with intellectual disability (2-4). In general, the greater the severity, the higher 
the prevalence (i.e., lesser in unselected population surveys and higher in the most severely ill).  
The accumulation of disease-relevant genomic data begs the question of how this should impact on 
clinical decision-making but the clinical knowledge base is limited. We need more treatment and 
management data to guide therapeutic choices for people with a pathogenic CNV and a severe 
psychiatric disorder, and to be able to address questions about familial risk. Although the associations of 
specific CNVs as etiological risk factors are secure, we do not now have an adequate knowledge base to 
inform the practice of clinical psychiatry. Figure 1b summarizes the content of the case report literature 
for two prominent CNVs, 22q11del and 16p11del/dup. For both, the emphasis is on diagnostic features, 
unusual presentations, and information particularly salient to clinical geneticists, neurologists, and 
pediatricians. In reviewing the literature in more detail, we found that the clinical knowledge base is 
very sparse – there are few data relevant to the question in the first paragraph: “how can you help me?”  
Although, as a group, these CNVs are a not uncommon etiological risk factor, the individual CNVs are 
rare and almost all are “orphan diseases” (i.e., impacting under 200,000 people in the US, lifetime 
prevalence < 0.06%; Supplemental Note 2). Accruing sizable samples for systematic study requires 
international consortia, considerable expense, and many years of effort. A prime example is the 
International 22q11.2 Deletion Syndrome (22q11DS) Brain Behavior Consortium (5). This consortium has 
assembled a sample of 1,616 psychiatrically well-characterized cases and obtained genomic data on 
>300 adults split evenly into those with schizophrenia and those without. The aims of this study are to 
understand how other genetic and non-genetic factors influence the expression of schizophrenia that 
may be of wider relevance to the general population, and to provide information on the precursors and 
antecedents of schizophrenia and to serve as a base for future longitudinal studies aiming to study the 
neurodevelopmental trajectories of deletion carriers. The outcomes of the study are beginning to 
appear and include the largest characterization of psychiatric outcomes in 22q11DS to date, and 
identification of childhood antecedents of psychotic outcomes (6, 7).  
It is reasonable to ask whether improved therapeutics are likely. We do not know. However, as a proof-
of-concept, Deborah Levy and colleagues recently reported two individuals with psychotic disorders and 
very rare CNV triplications of the glycine decarboxylase gene (8). Under the assumption of NMDA 
hypofunction due to increased glycine catabolism (and low levels of brain glycine and D-serine), they 
demonstrated clinical improvement in psychotic and mood symptoms with oral glycine supplementation 
(double-blind, placebo-controlled). If a clinician were to encounter a patient with this CNV in the future, 
this report would provide reasonable therapeutic guidance.  
We propose a systematic effort to obtain clinical data useful to management in clinical psychiatry. We 
effectively propose “clinical crowd-sourcing” that combines the advantages of a distributed effort with a 
comprehensive and systematic structure in order to yield high-quality case-report and case series 
knowledge to inform clinical psychiatric management. Our proposal has the following steps: 
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(1) Detection. We need to test more patients for CNVs. In fact, there is a strong case for universal testing 
for some psychiatric disorders, particularly early-onset and severely impairing conditions 
(moderate/severe intellectual disability and autism) as well as chronic psychotic disorders in adults. A 
positive result is relevant to clinical management – most large CNVs are multisystem disorders with 
increased risk of cardiac, neurological, endocrine, renal, hematological, and digestive complications (9). 
We encountered a patient whose idiopathic thrombocytopenia was chased after for years but was 
almost certainly a consequence of 22q11DS (10). We know of drug companies working on therapeutics 
for specific CNVs; if targeted medications become available in the future, we need to know the patients 
for whom these therapies may be indicated. The presence of a CNV can be relevant to reproductive 
planning, but the wide range of psychiatric and cognitive outcomes and incomplete penetrance calls for 
nuanced and informed genetic counseling (11).  
CNV testing is typically offered for children with ID, developmental delay or neurodevelopmental 
disorders. But CNVs are also risk factors for adult psychiatric cases particularly schizophrenia. What 
clinical features increase the likelihood of the presence of a CNV and should act as “flags” for targeted 
testing in adult psychiatry? We are not aware of systematic studies and there is clearly a pressing need 
for these as we argue below. However, based on current knowledge, we would highlight premorbid low 
intelligence, a history of childhood onset neurodevelopmental disorder, congenital malformations, 
dysmorphic features, and developmental delay (missing developmental milestones). A family history of 
schizophrenia or other neurodevelopmental disorders may also be relevant (although pathogenic CNVs 
frequently occur de novo and so a family history in a parent is often absent). Finally, we never discount 
the importance of the intuition of experienced clinicians, or the sense that a particular patient is 
distinctively different from others in the same diagnostic category. Examples here include very severe 
symptoms or extreme treatment refractoriness, and prominent physical co-morbidity.  
Exactly what test to order depends on the clinical context and on the availability and cost of 
technologies. We offer the following general considerations. First, consultation with a clinical geneticists 
and/or a genetic counsellor may be helpful. Second, for adult psychotic disorders, evaluation of CNVs 
would be a typical starting point. One technology for this purpose are chromosomal microarrays (CMA) 
which can identify the presence of large pathogenic CNVs (cost approximately $US 300). Third, for early 
onset, severe psychiatric disorders, a typical panel would include CMA and resequencing of the protein-
coding portion of the genome (whole exome sequencing) or whole genome sequencing. Applying the 
same technologies to both biological parents can help in prioritizing detected variants and in 
determining whether a variant is de novo or inherited.  
(2) Capture the needed data. In most instances, case reports that only describe the co-occurrence of a 
known CNV with a psychiatric disorder may not be particularly notable for associations that have been 
extensively documented. At the same time, there may be some novel or remarkable feature that would 
support publication (e.g., our report of a man with 22q11DS and Huntington’s Disease (10)).  
In our opinion, we need case reports and case series that have two key features: (a) comprehensive 
initial assessment and (b) systematic description of longitudinal course and the impact of therapeutic 
efforts.  
Initial assessment should include a multi-informant history of salient events in pregnancy, birth, 
childhood development, adolescence, and adulthood. Assessments or indications of intellectual function 
across development are very important (if not essential). Collecting such data from a psychiatric 
perspective is generally routine in clinical practice. However, for CNVs, there should be particularly 
attention to congenital and multi-system abnormalities across all organ systems. The presence of 
physical comorbidities should be sought, perhaps in collaboration with medical colleagues from other 
relevant specialties, bearing in mind those conditions known to be associated with a specific CNV. 
Page 4 
Finally, a thorough family history should be obtained with a focus on the range of neurodevelopmental 
disorders including schizophrenia that are associated with risk CNVs. Many would suggest that brain 
imaging using MRI is important.  
The critical missing ingredient is the longitudinal course and impact of therapeutics. There needs to be a 
systematic description of age-dated therapeutics across all modalities (pharmacological as well as 
behavioral and psychological). These need also be connected to age-dated assessments of functional 
capacity, occupation, role function, and inpatient, emergency, and outpatient treatment. Combining 
these data are needed to establish correlations as to what therapeutic strategies were optimal for this 
particular patient. In effect, a variant on the “N-of-one” clinical study.  
We note that modern data science (12) has many excellent and free tools for obtaining, refining, 
summarizing, and presenting complex longitudinal data. This is increasing easy to accomplish given the 
availability of electronic medical records. For example, Figure 1c took 5 minutes to make but captures 
25 years of pharmacotherapy for a person with highly treatment-resistant psychosis.  
(3) Publish a case report. It is then important to let the scientific community know what you have 
learned. The particular focus should be on what worked, what did not work, and what you might do 
differently if you could do it over. We strongly advocate for following explicit guidelines for the structure 
and content of a case report – for instance the CARE criteria, which were developed in the general 
medical context to improve completeness and transparency and facilitate the systematic aggregation of 
information across reports (13) (Table S3). In particular, the title should include “case report” and 
standard terms for the specific genetic change and the psychiatric diagnosis. Reasonable examples of 
CNV case reports/series may be found in these references (10, 14). There are multiple target journals for 
these case reports. Particularly detailed or notable case reports may appear in higher profile journals; 
however, it is critical for these case reports to be findable via inclusion in searchable resources like 
PubMed and PubMed Central. There are multiple open-access journals devoted to case reports and 
indexed in PubMed. A basic web search for “case report journals” found 10, and there are even 
overviews on the choice of case report journal (15).  
(4) Benefits and challenges. The potential benefits of what we propose are to allow other clinicians to 
benefit from the experiences of colleagues in the struggle to deliver effective clinical management and 
identify treatment options for individuals with rare pathogenic CNVs and severe mental illness. Many 
patients with CNVs experience protracted and stressful “diagnostic odysseys” in referrals to multiple 
specialists for organ-specific evaluations when, in the end, the root cause is a CNV with impacts on 
multiple systems. Minimizing time to CNV identification would minimize such odysseys and rapidly 
signpost potentially appropriate non-psychiatric assessments. Moreover, it is possible that detailed 
evaluation of these rare patients could yield therapeutic and etiological ideas relevant to patients with 
idiopathic forms of these disorders.  
“Bespoke therapeutics” may ultimately be an important benefit. For certain rare CNVs, the literature 
may suggest a therapy that is uniquely tailored to an individual with a particular CNV. Current examples 
include the use of oral glycine in CNV triplications of the glycine decarboxylase gene (8), and the 
anecdotal use of oral magnesium supplementation in Burnside-Butler syndrome (a 15q11.2 CNV 
deletion that impacts NIPA1 and NIPA2 which are involved in brain magnesium transport) (16). We 
contend that by rapidly sharing and disseminating clinical and therapeutic findings, we may be able to 
build on these small but important beginnings.  
A focus on copy number variation can also improve diagnostic classification. Many CNVs have highly 
variable clinical presentations that can include combinations of intellectual disability, specific learning 
impairments, autism, ADHD, anxiety/mood disorders, and psychotic disorders. In current diagnostic 
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schemas, these are coded according to the clinical presentation; however, while this has value, it is 
crudely akin to coding rash, fever, headache, photophobia, and altered mental status instead of N. 
meningitides meningitis. Given the range psychiatric disorders and medical comorbidities associated 
with these CNVs, a primary diagnosis that includes reference to the CNV may be more parsimonious and 
to capture and to alert clinicians to the full range of important sequelae.  
Several challenges are noted above, particularly the greater need for longitudinal and process outcome 
data (as opposed to merely documenting the co-occurrence of a CNV and a clinical presentation). An 
additional challenge is that advances in psychiatric and medical genetics mean that psychiatrists 
(particularly those in training) will need to understand how to generate, interpret, and explain genetic 
findings to their patients as well as how to use these data clinically (17). There are multiple ways to 
obtain direct-to-consumer genomics (many of dubious clinical utility), and clinicians will increasingly be 
faced with questions about their relevance. For interested readers, Table S1 contains a list of learning 
resources. There is clearly a need to embed genetics training deeply in residency training programs and 
to upskill practicing psychiatrists. Nurnberger et al. provide recommendations for psychiatry residency 
training and note “the basic principles of genetics…are essential to current psychiatric patient care” (18).  
A key challenge is clinical synthesis: e.g., for the patient introduced at the start of this article, how would 
a clinician efficiently, effectively, and accurately extract clinical guidance from the literature? Literature 
reviews are usually a great starting point (if they exist but with the caveat that they miss case reports 
since submission). Moreover, they may not cover the exact clinical need. We suggest there is an unmet 
need: we need a structured and curated on-line database that captures case report data at the interface 
of genetics and clinical psychiatry. This is largely informatics, but requires a funder to champion and 
support the idea. The idea is straightforward: to systematically capture the genetic mutation, the clinical 
phenotypes using a structured vocabulary (e.g., the Human Phenotype Ontology), therapeutics 
attempted, and therapeutic outcomes and adverse events. A reasonable model for this is the DECIPHER 
database in the UK (https://decipher.sanger.ac.uk). In addition, such a database could serve as the basis 
for research and grant applications to derive clinical and biological hypotheses as well as to support 
accrual of “orphan” patients for future systematic studies.  
The existence of a sizable body of cases reports – particularly if prepared to a high standard – would 
provide practical guidance for the clinical psychiatric management of people with a psychiatric disorder 
and a pathogenic CNV. If we were to have ten such reports for the vignette at the start of this essay (for 
a de novo 16p11 CNV, schizophrenia, and Asperger’s, “how can you help me?”), you could synthesize the 
reports to derive an empirical management plan. You might also discover a psychiatric colleague with 
particular expertise in treating people with 16p11 CNVs in adult patients and a conversation or email 
exchange could be helpful.  
Better case report data are literally better than nothing. However, ultimately, there is a need for more 
adequately powered studies that are able to relate specific genomic risk factors to clinical and 
neurocognitive outcomes and therapeutics. The individual CNVs are rare but the clinical psychiatric 
phenotypes with which they are associated are not, and the variable expressivity and pleiotropy seen 
offer an important opportunity to investigate the role of other genetic and environmental factors in 
modifying psychiatric outcomes and to deliver findings of relevance to psychiatric disorders more 
generally. They also offer an opportunity for studying groups of subjects in early childhood at high risk of 
later childhood and adult disorders and of studying the developmental course of psychiatric disorders 
and identifying potentially modifiable antecedents and modifiers. It is gratifying that NIMH has 
identified the potential of these studies and the need to assemble coordinated multidisciplinary and 
multi-site teams capable of combining genomic data with comprehensive dimensional and categorical 
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phenotype data. This is an excellent beginning but we believe that more attention/funding to this 
emerging area is required.  
Figure legends 
Figure 1a: CNVs associated with intellectual disability, developmental delay, autism, and/or 
schizophrenia (2, 19-21). Shown are ideograms of chr1-chr22, chrX, and chrY (hg19 coordinate system). 
The raw data are in Table S2. These 122 CNVs were merged into 57 regions for display (collapsing across 
sources, condition, and deletion/duplication status). The blue blocks show the location of CNVs 
association with intellectual disability, developmental delay, autism, and/or schizophrenia. These 
regions comprise 142.1 megabases or about 4.6% of the genome.  
Figure 1b: Word clouds of titles and abstracts from PubMed searches for case reports for 22q11 (left) 
and 16p11 (right). Font size and coloration indicate word frequency. These word clouds and more 
detailed inspection of the primary citations reveal little information to guide psychiatric therapeutics.  
Figure 1c: Illustration of graphical methods to succinctly portray a complex pattern of pharmacotherapy 
over 25 years. Using an electronic pharmacy record, the dosage of each psychiatric medicine per week 
was tabulated. The X-axis is age with each year comprising up to 52 thin, weekly slices. The Y-axis shows 
broad drug classes and the vertical sections within each class show the specific medications. The color of 
each vertical slice depicts the ratio of the prescribed amount of drug to “defined daily dose” specified by 
the World Health Organization for each drug (from very light to very dark red with the two darkest 
colors showing a ratio over 1). This person has received substantial trials of four typical antipsychotics 
and significant trials of four atypical antipsychotics (including around a year of clozapine). There were 
also extensive trials of valproate, lithium, and lorazepam. Adding measures of symptoms and function 
could allow clinical correlations of clinical efficacy.  
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